Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Register Now for the Targeted Therapies Patient Forum
Join our faculty April 6, 2019, in Philadelphia, PA to learn about the newest breakthroughs in Targeted Therapies for Lung Cancer
Have a chance to talk with the doctors about the newest information in targeted therapies. Some potential topics our faculty will be discussing include:
NGS: Current Status, Barriers and Emerging Targets
Liquid Biopsies as a New Option: How Does it Fit In?
What is the Role for Rebiopsy Today?
Presentations by Lung Cancer Subtypes - ALK, ROS1, EGFR, RET,MET, BRAF
Immunotherapy for Targeted Therapies - What Do We Know?
Controlling the Brain as a Separate Compartment
Online Communities - Support, Education & Partnership on Research
and time for discussion and Q&A
(**subject to change)
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…